dc.contributor.author | Onsøien, Mari Olsen | |
dc.contributor.author | Midtvedt, Karsten | |
dc.contributor.author | Reisæter, Anna Varberg | |
dc.contributor.author | Aasarød, Knut | |
dc.contributor.author | Waldum-Grevbo, Bård | |
dc.contributor.author | Vikse, Bjørn Egil | |
dc.contributor.author | Eriksen, Bjørn Odvar | |
dc.contributor.author | Åsberg, Anders | |
dc.date.accessioned | 2021-07-13T09:24:29Z | |
dc.date.available | 2021-07-13T09:24:29Z | |
dc.date.issued | 2021-03-25 | |
dc.description.abstract | <i>Background</i> - Hypertension in kidney transplant (KTx) recipients is common, affecting both patient and graft survival. Annual data from the Norwegian Renal Registry reveal that <50% of adult (>18 y) KTx recipients reach target blood pressure (BP) ≤130/80 mm Hg. The aim of this study was to identify the determinants of failure to achieve BP control.<br><br>
<i>Methods</i> - In conjunction with the 2018 annual data reporting, additional questions were added for recipients with BP >130/80 mm Hg (treating physician´s target BP for each patient, reasons for not achieving target, method of measurement).<br><br>
<i>Results</i> - Annual forms were received from 98% (3407 of 3486) of KTx recipients, with 1787 (52%) reporting a BP >130/80 mm Hg (“above-target” group). These recipients were older, mostly male, with higher body mass index and serum creatinine levels (<i>P</i> < 0.05) compared with patients with controlled hypertension (“on-target” group). Valid survey answers were available for 84% of the “above-target” group (Surv<sub>resp</sub>) with no significant demographic differences versus nonresponders (Surv<sub>nonresp</sub>). Among Surv<sub>resp,</sub> 32% were under antihypertensive dose titration, whereas dose-limiting side effects were reported in 7%. Target BP was confirmed to 130/80 mm Hg for 60% of Surv<sub>resp.</sub> In recipients for whom the treating physician set target BP >130/80 mm Hg, 51% did not reach these individual targets. The number of antihypertensive drugs was significantly higher in the “above-target” group versus “on-target” group (mean 2.1 ± 1.2 versus 1.8 ± 1.3) and 36% versus 25% used ≥3 antihypertensive drugs (<i>P</i> < 0.05). Automatic attended BP measurement was utilized by 51%.<br><br>
<i>Conclusions</i> - In KTx recipients, a higher BP target achievement seems possible, potentially in the range of 75%-80%. | en_US |
dc.identifier.citation | Onsøien, Midtvedt K, Reisæter AV, Aasarød K, Waldum-Grevbo B, Vikse BE, Eriksen BO, Åsberg A. Blood Pressure Treatment in Kidney Transplant Recipients—Can We Improve?. Transplantation direct. 2021;7(4):e688 | en_US |
dc.identifier.cristinID | FRIDAID 1901924 | |
dc.identifier.doi | 10.1097/TXD.0000000000001142 | |
dc.identifier.issn | 2373-8731 | |
dc.identifier.uri | https://hdl.handle.net/10037/21868 | |
dc.language.iso | eng | en_US |
dc.publisher | Lippincott, Williams & Wilkins | en_US |
dc.relation.journal | Transplantation direct | |
dc.rights.accessRights | openAccess | en_US |
dc.rights.holder | Copyright 2021 The Author(s) | en_US |
dc.subject | VDP::Medical disciplines: 700 | en_US |
dc.subject | VDP::Medisinske Fag: 700 | en_US |
dc.title | Blood Pressure Treatment in Kidney Transplant Recipients - Can We Improve? | en_US |
dc.type.version | publishedVersion | en_US |
dc.type | Journal article | en_US |
dc.type | Tidsskriftartikkel | en_US |
dc.type | Peer reviewed | en_US |